Want to see GB:GSK full AI Analyst Report?
GSK Stock Chart & Stats
1905.50 p
17.50 p(0.91%)
At close: 4:00 PM EDT
1905.50 p
17.50 p(0.91%)
Day’s Range― - ―
52-Week Range1,690.00 p - 2,282.00 p
Previous CloseN/A
Volume794.16K
Average Volume (3M)7.23M
Market Cap
£73.42B
Enterprise Value94.96B
Total Cash (Recent Filing)£2.96B
Total Debt (Recent Filing)£23.70B
Price to Earnings (P/E)15.3
Beta1.16
Next Earnings
Feb 03, 2027EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)1.08
Shares Outstanding4,045,430,700
10 Day Avg. Volume7,127,473
30 Day Avg. Volume7,229,529
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,095.57Price Target Upside9.97% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)1.79
Revenue Forecast (FY)£33.88B
Bulls Say, Bears Say
Bulls Say
Specialty Medicines GrowthBroad-based specialty-medicine growth across HIV, respiratory and oncology reduces reliance on a single product and supports a stronger long-term mix. Double-digit performance from several launches also indicates meaningful commercial traction for GSK’s differentiated portfolio.
Pipeline And Launch MomentumThe sharp acceleration in late-stage development expands GSK’s opportunity to replenish and diversify future revenue. Multiple approvals, launches and positive clinical readouts create several potential growth drivers rather than depending only on established medicines.
Cash Generation And ProfitabilityStrong operating cash flow and free cash flow give GSK internal funding for research, launches, business development and shareholder distributions. High profitability and recent cash-flow growth provide useful resilience while the company invests heavily in its pipeline.
Bears Say
Leverage And Interest BurdenGSK’s meaningful debt load reduces financial flexibility and makes earnings more sensitive to refinancing costs. Higher interest expense, including financing related to Nuvalent, can absorb cash that could otherwise support research, acquisitions or debt reduction.
Rising Investment And Restructuring CostsAccelerated oncology investment may strengthen the pipeline, but the near-term cost burden is substantial and is growing faster than sales. Higher R&D and restructuring charges can limit operating leverage and make earnings conversion less predictable during execution.
Vaccine And Inhaler Market PressurePressure across major commercial franchises creates a drag on portfolio growth even as newer medicines expand. Shingrix faces China ordering and inventory challenges, while inhaler pricing and competition can constrain revenue quality and margin durability.
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1690.00 p and its highest was 2282.00 p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £73.42B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 03, 2027 which is in 96 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 28, 2026. The company reported 0.546 p earnings per share for the quarter, beating the consensus estimate of 0.503 p by 0.043 p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 17 p which represents an annual dividend yield of 3.71%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.28.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,045,430,700 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.546 p in its last earnings report, beating expectations of 0.503 p. Following the earnings report the stock price went down -4.783%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£2,095.57 (9.97% Upside)
£2,095.57 (9.97% Upside)
Blogger Sentiment
Neutral
GB:GSK Sentiment 67%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth £2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 78%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.37%
12-Months-Change
Fundamentals
Return on Equity
28.35%
Trailing 12-Months
Asset Growth
16.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GlaxoSmithKline
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
2,095.57 p
▲(9.97% Upside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―











